Immune activation, smoking, and vaccine response.
Here, we tested the hypothesis that chronic immune activation might fuel interindividual variability in vaccine response in the model of hepatitis B virus vaccine in HIV-1-infected adults. We observed that the marker of inflammation soluble tumour necrosis factor receptor I (sTNFRI) is predictive for vaccine efficiency. We also established that the link between tobacco smoking and impaired vaccine response might be mediated by inflammation. These data are a step forward in personalized vaccination.
aInstitute of Human Genetics, CNRS UPR1142, Montpellier, France bINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, UPMC Paris 06 cAssistance Publique Hôpitaux de Paris (AP-HP), Public Health Unit, Hôpital Saint-Antoine dSorbonne Paris Cité, AP-HP, CIC Cochin Pasteur, Hôpital Cochin, Université Paris Descartes, Paris eInserm, F-CRIN, I-REIVAC, Paris fMontpellier University, Montpellier gImmunology Department, University Hospital, Nîmes, France. *Study group members are listed after the text. †OL and PC contributed equally to this work.
Mehwish
M
Younas
Fabrice
F
Carrat
Corinne
C
Desaint
Odile
O
Launay
Pierre
P
Corbeau
D000328:Adult; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000473:pathology*; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000473:pathology*; D008297:Male; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000097:blood; D000073869:Tobacco Smoking / Q000009:adverse effects*; D016896:Treatment Outcome
D017325:Hepatitis B Vaccines; D047888:Receptors, Tumor Necrosis Factor, Type I